These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 1620196)

  • 1. Discussion: subject selection, recruitment, and retention in longitudinal studies involving perinatal substance abuse and human immunodeficiency virus infection.
    Bandstra ES
    NIDA Res Monogr; 1992; 117():183-93. PubMed ID: 1620196
    [No Abstract]   [Full Text] [Related]  

  • 2. Perinatal substance abuse and AIDS: subject selection, recruitment, and retention.
    Rich KC
    NIDA Res Monogr; 1992; 117():166-82. PubMed ID: 1620194
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Subject recruitment and retention for longitudinal research: practical considerations for a nonintervention model.
    Streissguth AP; Guinta CT
    NIDA Res Monogr; 1992; 117():137-54. PubMed ID: 1620192
    [No Abstract]   [Full Text] [Related]  

  • 4. Discussion: measurement issues in the study of effects of substance abuse in pregnancy.
    Coles CD
    NIDA Res Monogr; 1992; 117():248-58. PubMed ID: 1620200
    [No Abstract]   [Full Text] [Related]  

  • 5. Discussion: research environment and use of multicenter studies in perinatal substance abuse research.
    Rich KC
    NIDA Res Monogr; 1992; 117():293-304. PubMed ID: 1620203
    [No Abstract]   [Full Text] [Related]  

  • 6. Discussion: dilemmas in research in perinatal addiction--intervention issues.
    Finnegan LP
    NIDA Res Monogr; 1992; 117():344-8. PubMed ID: 1620206
    [No Abstract]   [Full Text] [Related]  

  • 7. Who is it going to be? Subject selection issues in prenatal drug exposure research.
    Fried PA
    NIDA Res Monogr; 1992; 117():121-36. PubMed ID: 1620191
    [No Abstract]   [Full Text] [Related]  

  • 8. Methodological issues in obtaining and managing substance abuse information from prenatal patients.
    Sokol RJ; Ager JW; Martier SS
    NIDA Res Monogr; 1992; 117():80-97. PubMed ID: 1620212
    [No Abstract]   [Full Text] [Related]  

  • 9. Introduction to the Perinatal-20 treatment research demonstration program.
    Rahdert ER
    NIDA Res Monogr; 1996; 166():1-5. PubMed ID: 8818161
    [No Abstract]   [Full Text] [Related]  

  • 10. Issues in subject recruitment and retention with pregnant and parenting substance-abusing women.
    Howard J; Beckwith L
    NIDA Res Monogr; 1996; 166():68-86. PubMed ID: 8818166
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methodological issues in prevention research on drug use and pregnancy.
    Gilchrist LD; Gillmore MR
    NIDA Res Monogr; 1992; 117():1-17. PubMed ID: 1620189
    [No Abstract]   [Full Text] [Related]  

  • 12. Studies of prenatal drug exposure and environmental research issues: the benefits of integrating research within a treatment program.
    Kaltenbach KA; Finnegan LP
    NIDA Res Monogr; 1992; 117():259-70. PubMed ID: 1620201
    [No Abstract]   [Full Text] [Related]  

  • 13. Infection following treatment of mandible fractures: the role of immunosuppression and polysubstance abuse.
    Senel FC; Jessen GS; Melo MD; Obeid G
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2007 Jan; 103(1):38-42. PubMed ID: 17178492
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interventions for metabolic and endocrine complications of human immunodeficiency virus/acquired immune deficiency syndrome and illicit drug use.
    Khalsa JH; Genser S; Coates P; Francis H
    Clin Infect Dis; 2003; 37 Suppl 2():S37-42. PubMed ID: 12942372
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retinoids and drugs of abuse: implications for neurological disease risk in human immunodeficiency virus type 1 infection.
    Royal W; Vlahov D; Lyles C; Gajewski CD
    Clin Infect Dis; 2003 Dec; 37 Suppl 5():S427-32. PubMed ID: 14648459
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Maternal and fetal effects from substance use.
    Rayburn WF
    Clin Perinatol; 2007 Dec; 34(4):559-71, vi. PubMed ID: 18063105
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Neurologic manifestations of HIV infection in an infant].
    Echeverría Lecuona J; Oliveros Vela MP; Gaztañaga Expósito R; Torrado J; Ruiz Benito MA
    An Esp Pediatr; 1990 Jan; 32(1):88-9. PubMed ID: 2327672
    [No Abstract]   [Full Text] [Related]  

  • 18. Evaluation and management of substance use in HIV primary care.
    AIDS Inst Newsl; 1995 Jun; ():1-12. PubMed ID: 11367406
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mandatory reporting of child abuse and research on the effects of prenatal drug exposure.
    Besharov DJ
    NIDA Res Monogr; 1992; 117():366-84. PubMed ID: 1620208
    [No Abstract]   [Full Text] [Related]  

  • 20. How the environment affects research on prenatal drug exposure: the laboratory and the community.
    Coles CD
    NIDA Res Monogr; 1992; 117():271-92. PubMed ID: 1620202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.